The available evidence from preclinical studies and clinical studies showed that the SGLT2 inhibitors have distinctive morbidity and mortality reduction benefits in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.